Mounjaro weight loss in the first month is modest: you spend it on 2.5 mg, a starter dose, and no trial publishes a 4-week average in its text. What we do know is that in SURMOUNT-1, 82% of the participants analysed had lost at least 5% of their body weight by week 12, a ballpark of about 3 to 4 lb (1.5 to 2 kg) a month at 200 to 220 lb if the loss were steady, which it never is. Part of the first pounds can be water, and your curve will not look exactly like anyone else’s.
How much weight loss does Mounjaro give in the first month?
The first month of Mounjaro is a settling-in month rather than a peak-results month: you take four weekly injections of 2.5 mg, the smallest dose of the treatment, and the weight you lose is small and highly variable. The big trials report results at 72 weeks, not at 4 weeks, so any “official” first-month figure you see elsewhere deserves a close look.
If you want the story of those four weeks, appetite, nausea, how each injection feels, it already exists: your first month on Mounjaro, week by week. This article answers a different question, the numbers: how many pounds, how much of it is water, and what range counts as normal.
To set the scale, here is the finish line. In SURMOUNT-1, published in the New England Journal of Medicine, 2,539 adults with obesity or overweight, averaging 104.8 kg (about 231 lb) at the start, lost on average 15.0%, 19.5% or 20.9% of their body weight at 72 weeks depending on the final dose (5, 10 or 15 mg), against 3.1% on placebo. The first month is a very small slice of that road.
Why the starting dose of Mounjaro caps the first month
Mounjaro always starts at 2.5 mg once a week for 4 weeks, then moves to 5 mg and rises in 2.5 mg steps, no sooner than every 4 weeks, depending on response and tolerance. That ladder is written into the European product information, which applies in the EU and shapes how the drug is used in the UK and elsewhere.
The US label for the same molecule, sold in the United States as Zepbound for weight loss, is explicit about the job of that first dose: 2.5 mg is for treatment initiation, not a maintenance dose. It lets the body adjust and limits stomach side effects; it is not meant to deliver the final result. In SURMOUNT-1 the 5 mg target was reached at week 4, the 10 mg target at week 12 and the 15 mg target at week 20, according to the analysis by Ard and colleagues.
The practical consequence is simple. Even in people who respond very well to Mounjaro, month one happens at the lowest dose and does not represent what follows. Comparing your week-4 weigh-in with 6-month or 1-year averages compares a starting line with a finish line. For the months ahead, we broke down the average weight loss seen in clinical studies.
Mounjaro weight loss in the first month: how many pounds, as a ballpark?
None of the sources we opened gives the average weight loss at 4 weeks on Mounjaro: that value sits on the trial curves, not in their text, so we will not invent it. What can honestly be calculated is a ballpark from a published figure: 82% of the participants analysed in SURMOUNT-1 had lost at least 5% of their weight by week 12.
| Starting weight | 5% of body weight (week-12 threshold) | Per month, if the loss were steady |
|---|---|---|
| 70 kg (154 lb) | about 3.5 kg (7.7 lb) | about 1.2 kg (2.6 lb) |
| 80 kg (176 lb) | about 4 kg (8.8 lb) | about 1.3 kg (2.9 lb) |
| 90 kg (198 lb) | about 4.5 kg (9.9 lb) | about 1.5 kg (3.3 lb) |
| 100 kg (220 lb) | about 5 kg (11 lb) | about 1.7 kg (3.7 lb) |
| 110 kg (243 lb) | about 5.5 kg (12.1 lb) | about 1.8 kg (4 lb) |
Read the table as a rough guide, not a promise. Real loss is not steady: it depends on the dose, which goes up at week 5, on appetite, on weeks when nausea cuts your eating, and on where you start. These participants also had dietary counselling with a 500 kcal daily deficit and at least 150 minutes of activity a week, which may not describe you.
Water, glycogen, fat: what are you really losing in month one?
When you eat less, the first pounds are not all fat: the body draws on glycogen, a carbohydrate store held in the liver and muscles, and that glycogen is held with a lot of water. According to Kreitzman and colleagues, it is stored with three to four parts of water, so using it up lowers the scale faster than fat alone would.
Be clear about the reach of that finding: it comes from a very-low-calorie diet in 11 people over 4 days, not from a tirzepatide trial. We found no study that measures the exact split of water, fat and muscle in month one on Mounjaro. The mechanism is plausible, since the drug reduces what you eat, but its size in you cannot be quantified.
For the composition of weight lost over the long run, there is a solid reference. In a 160-person substudy of SURMOUNT-1, Look and colleagues used DXA scans to show that roughly 75% of the weight lost at 72 weeks was fat mass and 25% lean mass, and the same split appeared in the placebo group. It says nothing about month one, but it is a reminder that weight loss is never 100% fat.
- Weeks 1 to 2: the scale may move more than your waistline, partly because of water and glycogen. That is a mechanistic hypothesis, not a measurement on Mounjaro.
- Weeks 3 to 4: the decline gets steadier if appetite stays lower, but it can also stall for a while, which is common at a low dose.
- Beyond month one: about three quarters of the weight lost is fat, per the DXA substudy, which is why protecting muscle through food and activity matters.
Why do results vary so much from person to person?
Because response to Mounjaro is highly individual: in the SURMOUNT-1 trial, about one person in five starts slowly, which does not predict that the treatment will fail, and starting profile and the dose reached explain part of the gap. In the analysis by Ard and colleagues, 18% of adherent participants had lost less than 5% of their weight at week 12, against 82% who had passed that mark.
A slow start is not a failure. Of those 278 slower participants, 70% reached at least 5% loss by week 24 and 90% by week 72. Their final average loss was smaller (11.0% versus 22.5% for early responders) but still clinically meaningful. The authors conclude that continuing beyond 12 weeks may let more people reach a useful result.
The analysis also notes differences in profile. Slower responders included more men (45% versus 30%) and weighed more at baseline (110.2 kg versus 103.6 kg). The authors suggest several possible explanations, including lower drug exposure at higher body weight, without settling the question. Another study, by Kokkinos and colleagues, grouped people by their loss at week 8: early response was linked to greater loss at 72 weeks, with similar stomach tolerability.
Keep the useful reading: a very slow month does not predict failure, and a fast month does not guarantee what follows. Dose reached, duration, sex, starting weight, diet and tolerance all play a part. To see where you start from, you can check your BMI and weight-loss projection.
What is normal in the first month, and what is not
The first month on Mounjaro usually brings a modest loss, a smaller appetite and stomach side effects, which are the dominant adverse effects of the treatment. In the pooled trials cited by the US label, nausea was reported by 25% of people on 5 mg versus 8% on placebo, diarrhoea by 19% versus 8%, constipation by 17% versus 5% and vomiting by 8% versus 2%. Most of these episodes occurred during dose escalation and eased over time.
- Normal: a drop of half a pound to a few pounds over the month, a scale that bounces from day to day, a plateau of a few days, mild nausea that settles.
- Tell your doctor or pharmacist: no loss at all after several weeks combined with troublesome side effects, repeated vomiting, diarrhoea that will not stop, or being unable to drink. The label notes that these problems can lead to dehydration and affect the kidneys.
- Urgent: severe, persistent stomach pain, with or without vomiting, that may spread to the back. The label says to stop the medicine and seek care, as it can signal pancreatitis.
One last honest point: losing little in month one is not in itself a warning sign, and losing a lot is not in itself good news. If your loss worries you either way, do not change your dose on your own; talk to the person who follows you. To keep an objective record rather than rely on a single weigh-in, the MounjaGO app lets you enter a reference weight, log your weigh-ins and see them on a chart.
Limits of these data
These figures are clinical-trial averages, not individual promises. SURMOUNT-1 followed adults without diabetes who received structured diet and activity counselling, which does not always match real life. The early-response analyses are post hoc, meaning run after the fact, and cover participants who took at least 75% of their doses. Above all, the average loss at 4 weeks and the share of water on Mounjaro are not in the sources we consulted; the ballpark given here is a calculation, not a measurement.
Frequently asked questions
How much weight do you lose in the first month on Mounjaro?
There is no published official average at 4 weeks. As a ballpark, losing at least 5% by week 12, which 82% of analysed SURMOUNT-1 participants did, works out to roughly 1.5 to 2 kg (3 to 4 lb) a month at 90 to 100 kg if it were steady. Real results vary a lot from person to person.
Is it normal to lose almost nothing in the first month?
Yes, it happens. Month one is spent on 2.5 mg, an initiation dose. In SURMOUNT-1, 18% of adherent participants had lost less than 5% by week 12, and 90% of them went on to pass 5% by week 72. If nothing moves or you are worried, talk to your doctor.
Is first-month weight loss water or fat?
Probably a mix. Glycogen is stored with three to four parts of water, and using it lowers the scale at the start of eating less. That finding comes from a very-low-calorie diet, not from Mounjaro: the exact split on treatment in month one was not measured in the sources consulted.
What does Mounjaro before and after one month look like?
A subtle change. With four injections at 2.5 mg, visible differences are usually small, and your waist or the way clothes fit often shifts less than the scale. Telling comparisons are made at 3, 6 or 12 months, once the maintenance dose is reached.
Should I raise the dose if I lose little in month one?
No, not on your own. The move to 5 mg is planned after 4 weeks, and later increases are decided with your prescriber based on your response and tolerance. Never change the schedule or dose by yourself.
Sources
- Jastreboff A. M. et al., Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), New England Journal of Medicine, 2022. PMID 35658024, accessed on .
- Ard J. et al., Weight reduction over time in tirzepatide-treated participants by early weight loss response: post hoc analysis in SURMOUNT-1, Diabetes, Obesity and Metabolism, 2025. PMID 40677091, accessed on .
- Kokkinos A. et al., Tirzepatide efficacy and tolerability according to early weight response (SURMOUNT-1 and SURMOUNT-2), Diabetes, Obesity and Metabolism, 2026. PMID 42348366, accessed on .
- Look M. et al., Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study, Diabetes, Obesity and Metabolism, 2025. PMID 39996356, accessed on .
- Kreitzman S. N. et al., Glycogen storage: illusions of easy weight loss, excessive weight regain, and distortions in estimates of body composition, American Journal of Clinical Nutrition, 1992. PMID 1615908, accessed on .
- European Medicines Agency, Mounjaro: summary of product characteristics. ema.europa.eu, accessed on .
- Eli Lilly, Zepbound (tirzepatide): US prescribing information, DailyMed. dailymed.nlm.nih.gov, accessed on .
Medical disclaimer. This article is for information only and does not replace medical advice. The figures quoted are clinical-trial averages and do not predict your individual result. Nothing here is a dose or treatment recommendation: any decision to start, change or stop a treatment should be made with a doctor or pharmacist. Information current as of 5 October 2026.